drugset / Trial / NCT00129220

Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder

NCT00129220

Phase 3 Completed 224 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to confirm the efficacy of olanzapine in the treatment of manic or mixed symptoms associated with bipolar I disorder.

Timeline

Start
2005-07
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 2.5 mg Oral
Comparator Haloperidol Other / unclassified 10 mg Oral
Subject Olanzapine Small molecule 5 mg Oral
Subject Olanzapine Small molecule 20 mg Oral

Indications